ConductScience.org, home

Trial · NCT04105231

Registered outcomes16

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryPsychotic symptoms7 weeks follow-upPositive and Negative Syndrome Scale (PANSS) positive subscale, range 7-49. A measure of symptom severity. Higher values are worse.
SecondaryCannabis cessation (no use of cannabis within the past two weeks) (for current cannabis users at baseline)7 weeks follow-upTimeline follow back method
SecondaryCannabis use by self-reported days of cannabis use per week, since last study visit.7 weeks follow-upTimeline follow back method
SecondaryAmount of cannabis use per day, self-reported, since last study visit.7 weeks follow-upPSYSCAN cannabis questionnaire# 6-8
SecondaryResponse7 weeks follow-upResponse defined by PANSS total 25 percentile changes
SecondaryRemission7 weeks follow-up
Symptomatic remission is defined according to the Andreasen et al remission criteria. The criteria define symptomatic remission as a rating of no more than mild in four core positive and four core negative symptoms on the Positive and Negative Syndrome Scale (P1, P2 P3, N1, N4, N6, G5, G9,) that is sustained for ≥6 months. Because of the duration of this study, the requirement of 6 month will not be considered.
SecondaryGlobal illness severity7 weeks follow-up
Global illness severity is assessed with the Clinical Global Impression Scale (CGI). We will use the severity (CGI-S) at baseline and improvement (CGI-I) scores of the CGI at the following visits. Response will be defined as much improved or better on the CGI-I. The main item 'severity of illness' is measured on a 7-point Likert scale (from 1 'normal, not at all ill' to 7 'among the most extremely ill patients').
SecondaryPsychosocial functioning7 weeks follow-upPersonal and Social Performance Scale (PSP). Higher is better, range 1-100.
SecondaryNeurocognitive functioning7 weeks follow-upBrief Assessment of Cognition in Schizophrenia (BACS). Neurocognitive Test Battery. One composite score and six subscales.
SecondarySubjective well-being7 weeks follow-upSubjective Well-being under Neuroleptics Scale (SWN). A measure of health-related quality of life.
SecondaryCircadian rest-activity cycle7 weeks follow-upActigraphy. A wrist-worne device that measures kinetic energy.
SecondarySubjective sleep quality7 weeks follow-upPittsburgh Sleep Quality Index (PSQI). One total score, seven subscales.
SecondaryObjective sleep evaluation7 weeks follow-upPolysomnography (PSG). A measure of objective sleep variables
SecondaryMetabolomics7 weeks follow-upMarkers for cannabinoids, dopamine and serotonin and their precursors and metabolites in the blood
OtherAdverse events (AEs), discontinuation due to AEs, and serious adverse events (SAEs)From baseline to 2 weeks after end of treatmentSelf-report
OtherExtrapyramidal and other side effects7 weeks follow-upUdvalget for Kliniske Undersoegelser (UKU) short version A clinician-rated scale to assess antipsychotic side effects

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04105231/registered